Breaking News
Get 40% Off 0
🔎 See NVDA's full ProTips for an instant risks or rewards Claim 40% OFF
Close

Corbus Pharmaceuticals Holding (CRBP)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Corbus Pharmaceuticals Holding's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
26.9100 +3.6100    +15.49%
- Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 585,258
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 23.6840 - 28.5600
Corbus Pharmaceuticals Holding 26.9100 +3.6100 +15.49%

NASDAQ:CRBP Financials

 
A brief overview of the NASDAQ:CRBP financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Corbus Pharmaceuticals Holding over time.

Corbus Pharmaceuticals Holdings, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 10.05 million compared to USD 8.78 million a year ago. Basic loss per share from continuing operations was USD 2.27 compared to USD 2.11 a year ago. Diluted loss per share from continuing operations was USD 2.27 compared to USD 2.11 a year ago.For the nine months, net loss was USD 36.58 million compared to USD 31.47 million a year ago. Basic loss per share from continuing operations was USD 8.52 compared to USD 7.55 a year ago. Diluted loss per share from continuing operations was USD 8.52 compared to USD 7.55 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

CRBP Income Statement

Gross margin TTM -
Operating margin TTM 0%
Net Profit margin TTM 0%
Return on Investment TTM -86.86%
 Total Revenue  Net Income
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Total Revenue
Gross Profit -6.55 -4.25 -13.39 -6.24
Operating Income -9.49 -8.19 -17.3 -10.8
Net Income -10.05 -8.78 -17.74 -10.88

CRBP Balance Sheet

Quick Ratio MRQ 0.91
Current Ratio MRQ 0.99
LT Debt to Equity MRQ -
Total Debt to Equity MRQ 7,349.07%
 Total Assets  Total Liabilities
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Total Assets 36.28 43.72 51.65 66.31
Total Liabilities 35.97 34.2 35.19 33.32
Total Equity 0.311 9.52 16.46 32.99

CRBP Cash Flow Statement

Cash Flow/Share TTM -8.49
Revenue/Share TTM -
Operating Cash Flow  -22.76%
 Cash  Net Change in Cash
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -7.18 -7.8 -15.11 -7.45
Cash From Investing Activities 10.9 8.81 5.55 11.78
Cash From Financing Activities -0.821 0.018 -0.113 0.234
Net Change in Cash 2.9 1.02 -9.68 4.56
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CRBP Comments

Write your thoughts about Corbus Pharmaceuticals Holding
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
William Torpey
William Torpey Feb 09, 2024 10:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I expected as much. This was an international trial. If it does as well in the US trial, they will be on their way to getting FDA approval. Then the value, of this stock, will take off.
Tomi Haaksikari
Tomi Haaksikari Jan 29, 2024 2:05PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
to the moooooon!💪💪💪
Ricardo Munoz
Ricardo Munoz Jan 26, 2024 3:22PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
WOW worth the waiting! to the moon!
Pepa Flores
Pepa Flores Jan 26, 2024 9:44AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What has happened?
William Torpey
William Torpey Jan 26, 2024 9:44AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
A human trial (done in China) has produced excellent results on reducing hard cancerous tumors. US human trials are expected to commence this year!
Pepa Flores
Pepa Flores Jan 26, 2024 9:44AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Thanks. I foung the press release from the company and some news on google but minutes later my post. Now I have hopes to revover my money. And besides, really good news in the fight agains cancer.
Tomi Haaksikari
Tomi Haaksikari Mar 29, 2023 12:24PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
💪💪💪
Dericko Cooper
Dericko Cooper Oct 18, 2022 2:03AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Tech's Roe Visual
Dericko Cooper
Dericko Cooper Oct 18, 2022 2:02AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Tech's Roe Visual
Ali Masoud
Ali Masoud Oct 13, 2022 4:35AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Gogogo
Jan Dow
Jan Dow Dec 31, 2021 10:09AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Will goto 4 january 2022Source: trust me bruh
Leo Gao
Leo Gao Dec 31, 2021 10:09AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
bro predicted
Dan LSD
Dan LSD Dec 31, 2021 10:09AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
more prediction please!
Marcos GG
Marcos GG Nov 22, 2021 1:20PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
gogogo
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email